Navigation Links
FDA: Orphan Drug Workshops Scheduled For Feb. 25-26 and Aug. 3-4, 2010

Agency Experts to Provide Guidance on Applying for Orphan Drug Designation

SILVER SPRING, Md., Dec. 23 /PRNewswire-USNewswire/ -- As part of its continuing effort to make the agency more transparent and accessible, the FDA has scheduled a series of workshops about orphan drug designation for academics, biotechnology companies, and those unfamiliar with the process. The FDA can grant a special status, known as orphan designation, for drug products intended to treat rare diseases.


Orphan drugs are either drug or biologic products used to treat conditions affecting fewer than 200,000 people in the United States. Orphan drugs may be already-approved or experimental drugs.

The workshops will be held Feb. 25-26, 2010, in Claremont, Calif., and Aug. 3-4, 2010, in Minneapolis. At the workshops, participants will propose a specific drug for a specific rare disease and work on an orphan designation application to submit to the FDA at the conclusion of the workshop. To help participants develop strong applications, FDA staff will provide one-on-one regulatory help.

To obtain orphan drug designation, drugs must be for the treatment, prevention or diagnosis of a rare disease or condition. Designation also requires there be a medical rationale for expecting the proposed drug to be effective in the treatment, prevention, or diagnosis of that disease or condition.

Orphan designation qualifies the applicant to receive certain benefits, such as tax credits and marketing incentives, from the federal government in exchange for developing the drug. After designation, the drug must then be submitted for review through the FDA marketing approval process, which evaluates the drug for safety and efficacy.

During the past 25 years, the FDA has granted orphan drug designation to about 2,100 drugs, of which 344 have become approved products.

For more information:

Do a Designation: FDA Orphan Drug Workshops

Designating an Orphan Product: Drugs and Biologics

    Media Inquiries: Sandy Walsh, 301-796-4669,
    Consumer Inquiries: 888-INFO-FDA

SOURCE U.S. Food and Drug Administration

SOURCE U.S. Food and Drug Administration
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Hodgkins Lymphoma
2. Advanced Life Sciences Announces ALS-357 Granted FDA Orphan Drug Designation for Metastatic Melanoma
3. US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness
4. Knopp Neurosciences Receives Orphan Designation for KNS-760704 for Treatment of ALS
5. Voices to Unite in Los Angeles for 6,000 Children Orphaned Daily
6. Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma Multiforme
7. Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy
8. Antheras A-001 Receives Orphan Drug Status for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
9. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
10. Fovea Pharmaceuticals Receives Orphan Drug Designation from EC for RdCVF for the Treatment of Retinitis Pigmentosa
11. ActivBiotics Receives Orphan Drug Designation from the European Medicines Agency for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis Indication
Post Your Comments:
(Date:10/13/2015)... -- Families across the country have filed product ... pharmaceutical company,s blockbuster anti-nausea drug Zofran and congenital ... their fraudulent misrepresentations to prescribing physicians about the ...   Due to the large number of Zofran birth ... Panel on Multidistrict Litigation (JPML) has ordered that ...
(Date:10/13/2015)... LAS VEGAS , Oct. 13, 2015 ... field of vascular medicine and intervention through education and ... its annual conference,  VIVA 2015 . Sixteen trial results, ... be released for the first time on Monday and ... Vegas. --> --> ...
(Date:10/13/2015)... , Oct. 13, 2015   Generational Equity , ... businesses, is pleased to announce the acquisition of its ... Largo, Florida , by Meridian Biomedical, ... September 11, 2015. Florida ... --> Florida . To learn more, ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... 13, 2015 , ... The Lymphoma Research Foundation (LRF) – ... serving the lymphoma community through a comprehensive series of education programs, outreach initiatives ... Commitment to Cure last night at the Mandarin Oriental in New York City. ...
(Date:10/13/2015)... ... 13, 2015 , ... Wimbledon Health Partners , the ... as well as pioneering the way for high schools, colleges and universities to ... Levitt as Chief Financial Officer. Levitt brings over 20 years of financial experience ...
(Date:10/13/2015)... ... October 13, 2015 , ... The added calories and sugar in ... So what is a parent to do? Registered dietitians from Retrofit , the ... this time of year. , “Halloween is a high-calorie holiday,” said Dara Aronow, ...
(Date:10/13/2015)... ... October 13, 2015 , ... The American Institutes for Research ... health staff caring for students who have experienced sexual assault and other trauma. The ... House during the Violence Against Women Act's 21st anniversary. , AIR ...
(Date:10/13/2015)... ... 2015 , ... CURE Media Group, the nation’s leading digital ... with the International Waldenstrom’s Macroglobulinemia Foundation (IWMF) to expand education and ... physicians. , “Waldenstrom’s Macroglobulinemia is a so-called ‘orphan disease’ that typically does ...
Breaking Medicine News(10 mins):